Change in the number of votes relating to Biotie Therapies Corp.'s shares

Change in the number of votes relating to Biotie Therapies Corp.'s shares

ID: 256248

(Thomson Reuters ONE) -


Biotie Therapies Corp.          Stock Exchange Release   6 May 2013 at 11.15
a.m.

Change in the number of votes relating to Biotie Therapies Corp.'s shares

The Swiss subsidiary of Biotie Therapies Corp. ("Biotie" or the "Company"),
Biotie Therapies AG (previously Synosia Therapeutics Holding AG and Biotie
Therapies Holding AG) has conveyed Biotie shares against consideration pursuant
to the option programs as follows:

April 2013 Total (5/2011- Options % of the total
4/2013) outstanding amount of
shares

       290,875    6,885,463      7,671,728  1.7%




The conveyance of Biotie shares relates to the option plan of Synosia
Therapeutics Holding AG (currently Biotie Therapies Holding AG, "Synosia")
acquired by Biotie in February 2011. According to such Synosia share option
plan, options have been granted to employees, former directors and consultants.
In connection with the completion of the acquisition of Synosia, the option plan
was amended so that instead of shares in Synosia an aggregate maximum of
14,912,155 shares in Biotie may be subscribed based on the plan. Biotie issued
these 14,912,155 shares to its current subsidiary Synosia in connection with the
acquisition to be further conveyed to the option holders when they potentially
exercise their option rights in accordance with the terms and conditions of the
option program.

The conveyed shares previously held by the Company's subsidiary have not carried
any voting rights. The parent company Biotie does not own any treasury shares.
The conveyance does not affect the number of registered shares.

After the conveyances the changes are as follows:

The increase of vote A total amount of The number of the The total number




of the Company voting rights: Company's share held of registered
April 2013 by the Group shares
April 2013

290,875        444,684,046             452,710,738
 8,026,692




Turku, 6 May 2013

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900
e-mail: virve.nurmi(at)biotie.com

DISTRIBUTION
NASDAQ OMX Helsinki Ltd
Main Media
www.biotie.com




This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Biotie Therapies Oyj via Thomson Reuters ONE
[HUG#1699377]




Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  European approval granted for Pexion® - innovative treatment for canine epilepsy discovered by BioCrea, developed and launched by Boehringer Ingelheim Ahlstrom announces price increases for specialty papers worldwide
Bereitgestellt von Benutzer: hugin
Datum: 06.05.2013 - 10:16 Uhr
Sprache: Deutsch
News-ID 256248
Anzahl Zeichen: 3429

contact information:
Town:

Turku



Kategorie:

Business News



Diese Pressemitteilung wurde bisher 184 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Change in the number of votes relating to Biotie Therapies Corp.'s shares"
steht unter der journalistisch-redaktionellen Verantwortung von

Biotie Therapies Oyj (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Biotie: Selincro Launched in the United Kingdom ...

TURKU, FINLAND -- (Marketwired) -- 05/06/13 -- Biotie today announced that its partner H.Lundbeck A/S (Lundbeck) has launched Selincro in the United Kingdom. According to the terms of the license agreement between Biotie and Lundbeck for Selincro, B ...

Biotie: Selincro Launched in First European Markets ...

TURKU, FINLAND -- (Marketwired) -- 04/22/13 -- BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 22 April 2013 at 9:00 a.m.Biotie today announced that its partner H.Lundbeck A/S (Lundbeck) has started launching Selincro™ in the first European markets, ...

Alle Meldungen von Biotie Therapies Oyj



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z